Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been assigned an average rating of “Moderate Buy” from the eighteen analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $190.8571.

A number of equities research analysts have recently commented on CRL shares. William Blair raised Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research report on Monday, October 6th. Mizuho boosted their target price on Charles River Laboratories International from $155.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Baird R W raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird upgraded shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $178.00 to $199.00 in a report on Thursday, November 6th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Avantax Advisory Services Inc. increased its holdings in Charles River Laboratories International by 18.3% during the first quarter. Avantax Advisory Services Inc. now owns 2,021 shares of the medical research company’s stock worth $304,000 after buying an additional 312 shares during the last quarter. Cetera Investment Advisers lifted its position in shares of Charles River Laboratories International by 7.3% in the first quarter. Cetera Investment Advisers now owns 9,664 shares of the medical research company’s stock valued at $1,455,000 after buying an additional 660 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Charles River Laboratories International by 11.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 15,926 shares of the medical research company’s stock valued at $2,397,000 after acquiring an additional 1,648 shares during the period. Exencial Wealth Advisors LLC bought a new position in shares of Charles River Laboratories International in the first quarter valued at about $393,000. Finally, ASR Vermogensbeheer N.V. bought a new position in Charles River Laboratories International in the 1st quarter valued at about $232,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 5.8%

NYSE:CRL opened at $184.88 on Thursday. The firm has a market capitalization of $9.10 billion, a price-to-earnings ratio of -118.51, a PEG ratio of 6.22 and a beta of 1.63. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $202.72. The business’s 50-day moving average price is $173.35 and its two-hundred day moving average price is $160.98. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. During the same period in the prior year, the business posted $2.59 EPS. Charles River Laboratories International’s revenue was down .5% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).